Business & Financial News, Breaking US & International News | Reuters
Edition:
United States

Biotechnology & Medical Research

Page 2

Chiome Bioscience to offer early-retirement program

Monday, 15 Feb 2016 01:30am EST

Chiome Bioscience Inc:To offer an early-retirement program to 60 employees.Offering time from middle May.The company expects 11 employees to take up the offer.Says the employees who take up the offer will retire on June 30.The company will provide retirement payment to the retiring employees.

Ina Research announces result of early-retirement program and expects extraordinary loss for FY 2016

Thursday, 24 Dec 2015 03:00am EST

Ina Research Inc:Says 38 employees took up the offer of the early-retirement program.Effective date of retirement is Feb. 20, 2016.A premium will be added to the normal retirement allowance of eligible applicants.Says eligible applicants will also have the option to receive job-placement assistance.Expected extraordinary loss of about 70 mln yen for FY ending March 2016.

Addex Therapeutics moves R&D operations to Geneva's Campus Biotech

Monday, 7 Dec 2015 01:00am EST

Addex Therapeutics:Moves R&D operations to Geneva's Campus Biotech.

Medical&Biological Laboratories to merge wholly owned subsidiary

Tuesday, 17 Nov 2015 01:00am EST

Medical&Biological Laboratories Co Ltd:Says to merge a wholly owned Japan-based subsidiary that has been engaged in research, development and sale of reagent for basic research.The subsidiary to be dissolved after transaction.Planned effective Jan. 1, 2016.

NanoenTek to merge with wholly owned subsidiary

Tuesday, 20 Oct 2015 12:56am EDT

NanoenTek Inc:To merge with a wholly owned subsidiary, Bio Focus Co., Ltd., which is engaged in the manufacturing of medical apparatus and instruments.Merger effective date of Jan. 5, 2016 and registered date of Jan. 1, 2016.The company will survive and the subsidiary will be dissolved after the merger.

Medivir to merge research and development units

Tuesday, 15 Sep 2015 08:00pm EDT

Medivir AB:Says to merge research and development and implement changes within the management group.Says its research and development operations will be merged into a joint unit as of Oct. 1.Medivir will also create a new function to house all regulatory skills and areas of responsibility.

Morphosys aims to push forward drug development

Tuesday, 8 Sep 2015 01:31am EDT

Morphosys AG:Says lead cancer program MOR208 to be examined in numerous combination studies in hematological cancers.Says aspires to become a fully-integrated and commercial biopharmaceutical organization with its own products on market.Says will commence two phase 2 trials of mor208 in diffuse large b cell lymphoma (dlbcl) and chronic lymphocytic leukemia (cll) in near future.

Pharmadax announces merger between subsidiaries

Thursday, 13 Aug 2015 06:20am EDT

Pharmadax Inc:Announces merger between a Foshan-based pharmacy wholly owned subsidiary and a Foshan-based biotechnology wholly owned subsidiary and the biotechnology subsidiary will dissolve after merger in one year.

Tonghua Dongbao Pharmaceutical to merge with subsidiary

Thursday, 6 Aug 2015 08:00pm EDT

Tonghua Dongbao Pharmaceutical Co Ltd:To merge with Tonghua-based wholly owned pharmaceutical subsidiary.Merger record date June 30.

Albany Molecular Research Inc to close Holywell U.K. API Manufacturing Facility

Thursday, 2 Apr 2015 04:05pm EDT

Albany Molecular Research Inc:Decides to close its Holywell, U.K. facility following a consultation process with employee representatives.Holywell site provides chemical development services and small- and large scale-manufacturing services of active pharmaceutical ingredients (API) and intermediates.AMRI will transition activities at the Holywell site to other facilities within the AMRI network and plans to cease operations at the site by the end of 2015.Closure of the site is expected to affect about 62 positions.

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary

Analyst Research

Report Title Price
Provider : Thomson Reuters StreetEvents
$75.00
Provider : Thomson Reuters StreetEvents
$75.00
Provider : Edison Investment Research
$10.00
Provider : Thomson Reuters StreetEvents
$75.00
Provider : Edison Investment Research
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.